⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

May 2, 2024Open Access

Figure S5 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary Figure S5: Combined loss of PVRL2 and PVR loss does not further inhibit tumor growth.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yang et al. (2024) studied this question.

synapsesocial.com/papers/68e6bea1b6db64358763e7be https://doi.org/10.1158/2326-6066.25736093.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S2 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways2024
2Figure S4 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways2024
3Figure S3 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways2024
4Figure S1 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways2024
5Table S1 from PVRL2 Suppresses Antitumor Immunity through PVRIG- and TIGIT-independent Pathways2024